CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 15 pages
ACIP HPV Vaccines Work Group Next steps Lauri E. Markowitz, MD Co-Lead, ACIP HPV Vaccines Work GroupNational Center for Immunization & Respiratory Diseases Advisory Committee on Immunization Practices April 15, 2025 ▪Wording of the recommendation for age at routine HPV vaccination ▪Number of doses in the recommended HPV vaccination seriesQuestions being considered by ACIP HPV Vaccines WG 2 Wording of the age for routine HPV vaccination October 2024 ACIP meeting ▪Introduction and historical…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 4 pages
ACIP Cytomegalovirus (CMV) Vaccines Workgroup Introduction Denise Jamieson, MD Chair, CMV Vaccines Workgroup April 15th, 2025National Center for Immunization & Respiratory Diseases ACIP Members •Denise Jamieson (WG chair) •Bonnie Maldonado Liaisons •David Kimberlin (AAP) •Liat Greenwood Chernoff (ACNM) •Naima Joseph (ACOG) •Tabitha Hanson (AIM) •Leisha Nolen (CSTE) •Ajit Limaye (IDSA) •Caleb Lyu (NACCHO) •Maria Carrillo -Marquez (PIDS)ACIP CMV WG Members Ex Officio Members •Douglas Pratt…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 21 pages
ACIP CMV Vaccine Workgroup Cytomegalovirus (CMV) and congenital CMV (cCMV) Epidemiology and Disease Burden Tatiana M. Lanzieri, MD, MPH ACIP CMV WG Co -Lead April 15th, 2025 Measles, Rubella and CMV Epidemiology TeamViral Vaccine Preventable Diseases BranchDivision of Viral DiseasesNational Center for Immunization & Respiratory Diseases Review epidemiology and disease burden of CMV and cCMVObjectives More than 16,000 children born with cCMV infection in the U.S. every year – 4.5 per 1,000…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 25 pages
© 2025 Moderna, inc. All rights reserved. 1 Overview of mRNA -1647: Investigational CMV Vaccine ACIP Robert Paris, MDApril 15, 2025 © 2025 Moderna, inc. All rights reserved. 2 Outline of Presentation •Unmet medical need for a CMV vaccine •Description of Moderna’s investigational CMV vaccine •Overview of clinical program •Phase 2 safety and immunogenicity study results •Design of ongoing Phase 3 efficacy trial •Summary © 2025 Moderna, inc. All rights reserved. 3 Impact and Global Burden of…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 11 pages
ACIP CMV Vaccine Workgroup Initial Considerations for CMV Vaccine Policy Tatiana M. Lanzieri, MD, MPH ACIP CMV WG Co -Lead April 15th, 2025 Measles, Rubella and CMV Epidemiology TeamViral Vaccine Preventable Diseases BranchDivision of Viral DiseasesNational Center for Immunization & Respiratory Diseases The burden of congenital CMV is substantial but awareness is low Need to assess vaccine acceptability and feasibility of implementation Primary maternal infections have a higher risk of…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 14 pages
U.S. Measles Update April 15, 2025Centers for Disease Control and Prevention National Center for Immunization & Respiratory Diseases CAPT David Sugerman, MD MPH FACEP, USPHS Senior Scientist, 2025 Measles Response Division of Viral Diseases / National Center for Immunization and Respiratory Diseases US Centers for Disease Control and Prevention (CDC) History of measles cases in the U.S., 1962 –2023 †Measles was declared eliminated in the U.S. in 2000 by WHO/PAHO. Elimination is defined as the…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 8 pages
Introduction to Meningococcal Vaccines Session Jamie Loehr, MD Advisory Committee on Immunization Practices April 16, 2025National Center for Immunization & Respiratory Diseases 1 3 Terms of Reference GSK Pentavalent (MenABCWY) Vaccine MenQuadfi Use in Infants Adolescent Schedule Change 2 of 8 3 Terms of Reference GSK Pentavalent (MenABCWY) Vaccine –Licensure: February 14, 2025 –ACIP Vote: April 16, 2025 (today) MenQuadfi Use in Infants –Licensure: May 2025 (anticipated) –ACIP Vote: …
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 56 pages
GSK Pentavalent ( MenABCWY ) Vaccine: Review of Updated EtR and Work Group Considerations Sarah Schillie, MD, MPH, MBA Advisory Committee on Immunization Practices April 16, 2025National Center for Immunization & Respiratory Diseases 1 The findings and conclusions in this report are those of the authors and do not necessarily represent the official position o f the U. S. Centers for Disease Control and Prevention. Meningococcal Vaccine Recommendations 2 of 56One MenACWY dose at age 11…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 13 pages
VFC Resolution Update: Meningococcal Vaccines Jeanne Santoli, MD, MPH April 16, 2025National Center for Immunization & Respiratory Diseases •Orange font/highlight in the presentation is used to indicate changes to the resolution in comparison to the prior approved version.Note •The purpose of this resolution is to update the resolution to incorporate a new combination pentavalent vaccine. Purpose of the Resolution Eligible Groups • Children aged 2 months through 10 years who are at…